Tradestie Institutional Equity Comparison Engine

BHST vs BGM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BGM Overall Edge

BGM Captures Institutional Edge (1โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BGM Group Ltd. Class A Ordinary Shares (BGM) driven by superior Momentum & Technical while BHST counters with relative strength in Growth & Margin. Fundamentally, BHST trades at N/M Forward P/E with -18.0% operating margin (+3.8% YoY revenue) versus BGM at N/M Forward P/E and -23.4% operating margin (+69.8% YoY). In options structure, BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BGM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BHST N/M vs BGM N/M Fwd P/E
Growth & Margin Winner BHST
Op Margin -18.0% vs -23.4% ยท YoY +3.8% vs +69.8%
Momentum & Technical Winner BGM
1Y -79.4% vs -17.5% ยท 52W Pos 6% vs 74%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
1M Return -22.62%
1Y Return -79.4%
Forward P/E N/M
Unified AI Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
1M Return -21.57%
1Y Return -17.53%
Forward P/E N/M
Unified AI Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BHST -79.4% BGM -17.53% Spread: +73.31 pp (BGM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BHST TTM Op. Margin: -18.0% BGM TTM Op. Margin: -23.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHST vs BGM. Trailing 12-month operating profitability (BHST -18.0% vs BGM -23.4%) and valuation multiples (BHST N/M vs BGM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BHST (2) vs BGM (6)
Institutional Metric BHST BGM Criterion Row Winner
Market Capitalization Scale $29.9M $108.6M Larger Scale BGM
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +3.8% +69.8% Higher Growth BGM
Operating Margin (TTM) Profitability -18.0% -23.4% Higher Margin BHST
Net Profit Margin Profitability -31.2% -44.2% Higher Margin BHST
Return on Equity (ROE) Capital Efficiency -142.5% -7.4% Higher ROE BGM
52-Week Range Position Momentum 6% ($1โ€“$7) 74% ($0โ€“$11) Stronger Trend BGM
Beta / 30D Volatility Risk Regime 0.25ฮฒ ยท 86% Vol 3.69ฮฒ ยท 80% Vol Lower Realized Risk BGM
Unified Institutional Score Composite Signal 58.2 / 100 (HOLD) 59.6 / 100 (HOLD) Higher Composite BGM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BHST vs BGM Buy Guide
BHST UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BHST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BGM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BHST nor BGM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.